| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jong Lyul Lee, Seon Ae Roh, Chan Wook Kim, Yi Hong Kwon, Ye Jin Ha, Seon-Kyu Kim, Seon-Young Kim, Dong-Hyung Cho, Yong Sung Kim and Jin Cheon Kim |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Korea Research Foundation |
2016R1E1A1A02919844 |
| the Asan Institute for Life Sciences, Asan Medical Center |
2016-710 |
| the Korea Research Foundation |
2017R1A2B1009062 |
|
| Corresponding Author |
Jin Cheon Kim, MD, PhD, Doctor, Doctor, Professor, Surgeon, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. jckim@amc.seoul.kr |
| Key Words |
Colorectal cancer; Prognosis; Immunotherapy; Signaling lymphocytic activation molecule family, member 7; Triggering receptor expressed on myeloid cells 1 |
| Core Tip |
The current study showed that in the patients with stage IV colorectal cancer (CRC) and a higher 19-gene based risk classifier score, the target-regimen-specific progression-free survival (PFS) was significantly increased compared with the 5-fluorouracil-regimen-specific PFS. Using another 10 validate set, down-regulation of signaling lymphocytic activation molecule family, member 7 (SLAMF7) and up-regulation of triggering receptor expressed on myeloid cells 1 were identified in primary and metastatic tumors compared with normal tissue. In CRC cells expressing SLAMF7 that were co-cultured with a monocytic cell line, levels of CD68 and CD73 were significantly lower at day 5 of co-culture than at day 0. |
| Publish Date |
2019-03-20 05:32 |
| Citation |
Lee JL, Roh SA, Kim CW, Kwon YH, Ha YJ, Kim SK, Kim SY, Cho DH, Kim YS, Kim JC. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer. World J Gastroenterol 2019; 25(11): 1341-1354 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i11/1341.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i11.1341 |
